Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis (Q38176549)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 January 2014

Language	Label	Description	Also known as
English	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis	scientific article published on 07 January 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

0 references

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

0 references

10

object named as

Maya H Buch

0 references

Cécile Gaujoux-Viala

3

object named as

Cecile Gaujoux-Viala

0 references

9

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

7

object named as

Laure Gossec

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Robert Landewé

8

object named as

Robert Landewe

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

object named as

Sofia Ramiro

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

author name string

Jackie L Nam

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Cecile Gaujoux-Viala

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Kaoru Takase

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Mario Leon-Garcia

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

7 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

516-528

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The role of biosimilars in the treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Therapies for active rheumatoid arthritis after methotrexate failure

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-204577

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38176549&oldid=1745941811"